Syndax Pharmaceuticals (SNDX) Finished Goods (2024 - 2026)

Syndax Pharmaceuticals' Finished Goods history runs 3 years deep, the most recent figure standing at $1.4 million for Q1 2026.

• In Q1 2026, Finished Goods rose 1284.0% year-over-year to $1.4 million; the TTM figure through Mar 2026 stood at $1.4 million (up 1284.0% YoY), while the FY2025 annual figure was $1.6 million, up 4386.11% from the prior year.
• Finished Goods was $1.4 million for Q1 2026 at Syndax Pharmaceuticals, down from $1.6 million in the prior quarter.
• In the past five years, Finished Goods ranged from a high of $2.2 million in Q2 2025 to a low of $36000.0 in Q4 2024.
• Historically, Finished Goods has averaged $1.3 million across 3 years, with a median of $1.5 million in 2025.
• The sharpest annual moves came in 2025 and 2026: Finished Goods jumped 4386.11% in 2025, then soared 1284.0% in 2026.
• A 3-year view of Finished Goods shows it stood at $36000.0 in 2024, then surged by 4386.11% to $1.6 million in 2025, then dropped by 14.3% to $1.4 million in 2026.
• The last three Finished Goods figures came in at $1.4 million (Q1 2026), $1.6 million (Q4 2025), and $2.2 million (Q3 2025), per Business Quant data.